Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science ...

Researchers at the University of California San Diego have found an unusual ally in the quest to make cancer diagnosis faster ...

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

A novel AI model was able to achieve 99.86% accuracy for diagnosing skin conditions, even in people with darker skin tones or ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer (NSCLC) in its ongoing Phase 2a study. IMM-1-104 is currently in a Phase 1/2a study ...

Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...